
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Vonoprazan–Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Vonoprazan–Tetracycline Dual Regimen as Rescue Therapy for Helicobacter pylori Infection: Randomized Controlled Trial</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastroenterology, Accepted 6 January 2026</li>
<li style="margin-left: 0px;">Topic: Helicobacter pylori rescue therapy (vonoprazan-tetracycline dual regimen)</li>
<li style="margin-left: 0px;">Author(s): Gao W, Li J, Yang G, et al.</li>
</ul>
<details><summary><strong>1. Study Background and Rationale</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">H. pylori is a Gram-negative bacterium colonizing the human stomach, affecting nearly half of the global population</li>
<li style="margin-left: 0px;">Antimicrobial treatment remains primary approach to limit bacterial transmission, promote gastric lesion healing, and reduce gastric cancer risk</li>
<li style="margin-left: 0px;">Simplified dual regimens using a single sensitive antibiotic have emerged as feasible alternative with growing challenge of antibiotic resistance</li>
<li style="margin-left: 0px;">In Asia, dual therapy with vonoprazan and amoxicillin has demonstrated high eradication rates and good tolerability</li>
<li style="margin-left: 0px;">Tetracycline serves as compelling alternative due to persistently low resistance rate (typically &lt;3%) and established role in bismuth quadruple therapy</li>
<li style="margin-left: 0px;">Prior retrospective study showed VT dual regimen achieved eradication rate of 90.9% (40/44) as rescue therapy in patients with prior treatment failure</li>
</ul>
</div></details>
<details><summary><strong>2. Study Design and Methods</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>2.1 Trial Overview</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prospective, open-label, randomized controlled non-inferiority trial conducted from February 2024 to July 2025</li>
<li style="margin-left: 0px;">Conducted at Peking University First Hospital, a tertiary medical center in Beijing, China</li>
<li style="margin-left: 0px;">Approved by Ethics Committee of Peking University First Hospital; conducted in accordance with Declaration of Helsinki</li>
<li style="margin-left: 0px;">Registered at chictr.org.cn (ChiCTR2400080705); followed CONSORT guidelines</li>
</ul>
</div></details>
<details><summary><strong>2.2 Participants</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Eligibility</strong>: Adults aged 18-80 years with confirmed H. pylori infection who experienced at least one prior eradication failure</li>
<li style="margin-left: 0px;"><strong>Exclusion criteria</strong>:</li>
<li style="margin-left: 20px;">Prior use of regimen containing PPI + bismuth + tetracycline + metronidazole in combination</li>
<li style="margin-left: 20px;">Use of antibiotics, bismuth, or PPI within 4 weeks prior to enrollment</li>
<li style="margin-left: 20px;">Pregnancy or breastfeeding</li>
<li style="margin-left: 20px;">Severe comorbidities (advanced hepatic, cardiac, or renal disease; malignancy; alcohol dependence)</li>
<li style="margin-left: 20px;">Known hypersensitivity to study medications</li>
<li style="margin-left: 20px;">Participation in another clinical drug trial within 3 months</li>
<li style="margin-left: 20px;">Inability to communicate effectively due to psychiatric conditions or severe neurosis</li>
<li style="margin-left: 0px;"><strong>Confirmation of infection</strong>: Positive 13C-urea breath test (UBT; 75 mg 13C-urea)</li>
</ul>
</div></details>
<details><summary><strong>2.3 Randomization and Interventions</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Allocation</strong>: 1:1 ratio to VT dual therapy or standard bismuth quadruple therapy (BQT)</li>
<li style="margin-left: 0px;"><strong>VT regimen</strong>: Vonoprazan 20 mg b.i.d. + tetracycline 500 mg t.i.d. for 14 days</li>
<li style="margin-left: 0px;"><strong>BQT regimen</strong>: Lansoprazole 30 mg b.i.d. + colloidal bismuth 150 mg t.i.d. + tetracycline 500 mg t.i.d. + metronidazole 400 mg t.i.d. for 14 days</li>
<li style="margin-left: 0px;"><strong>Dosing instructions</strong>: Vonoprazan, lansoprazole, and bismuth taken ~30 minutes before meals; tetracycline and metronidazole taken immediately after meals</li>
<li style="margin-left: 0px;"><strong>Randomization</strong>: Computer-generated random number sequence with block size of 4; assignments concealed in sequentially numbered, opaque, sealed envelopes</li>
</ul>
</div></details>
<details><summary><strong>2.4 Outcomes</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Primary outcome</strong>: Rate of successful H. pylori eradication determined via 13C-urea breath testing at 8-week follow-up (6 weeks after treatment completion)</li>
<li style="margin-left: 0px;"><strong>Secondary outcomes</strong>: Adverse event frequency and severity, medication adherence</li>
<li style="margin-left: 0px;"><strong>Adverse events graded</strong>: None; mild (transient, easily tolerated); moderate (noticeable interference with routine activities); severe (significant impact on daily functioning, hospitalization, or death)</li>
<li style="margin-left: 0px;"><strong>Adherence definition</strong>: Inadequate if &lt;80% of prescribed doses taken</li>
</ul>
</div></details>
<details><summary><strong>2.5 Sample Size and Statistical Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">One-sided significance level α = 0.025 (Bonferroni correction: α = 0.0125 per comparison)</li>
<li style="margin-left: 0px;">Statistical power: 80% (β = 0.20); non-inferiority margin predefined at 10%</li>
<li style="margin-left: 0px;">Expected eradication rate for BQT as rescue therapy: 88%</li>
<li style="margin-left: 0px;">Required sample size: 166 patients per group</li>
<li style="margin-left: 0px;">Planned total sample size: 350 participants (175 per arm) to account for ~5% dropout</li>
<li style="margin-left: 0px;"><strong>Analysis populations</strong>:</li>
<li style="margin-left: 20px;">ITT: all enrolled patients with at least 2 months follow-up (loss to follow-up = treatment failure)</li>
<li style="margin-left: 20px;">mITT: patients who received ≥1 dose and completed 13C-UBT ≥6 weeks after treatment</li>
<li style="margin-left: 20px;">PP: patients who completed follow-up and took ≥80% of prescribed medications</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Patient Enrollment and Baseline Characteristics</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Enrollment Flow</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Screened</strong>: 382 individuals</li>
<li style="margin-left: 0px;"><strong>Randomized</strong>: 350 patients (175 VT group, 175 BQT group)</li>
<li style="margin-left: 0px;"><strong>Final follow-up completed</strong>: July 2025</li>
<li style="margin-left: 0px;"><strong>Lost to follow-up</strong>: 5 patients in VT group, 6 in BQT group (excluded from mITT; classified as treatment failure in ITT)</li>
<li style="margin-left: 0px;"><strong>Discontinued treatment</strong>: 2 patients in VT group, 16 in BQT group</li>
<li style="margin-left: 0px;"><strong>Excluded from PP analysis</strong>: 7 VT patients, 22 BQT patients (total 29)</li>
</ul>
</div></details>
<details><summary><strong>3.2 Baseline Demographics</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Age</strong>: VT group mean 48 (SD 13.4) years, range 18-77; BQT group mean 45.7 (SD 12.1) years, range 18-73 (P=0.10)</li>
<li style="margin-left: 0px;"><strong>Sex</strong>: VT 60M/115F; BQT 66M/109F (P=0.58)</li>
<li style="margin-left: 0px;"><strong>Body weight</strong>: VT 63.5 kg (SD 12.4); BQT 63.3 kg (SD 11.2) (P=0.90)</li>
<li style="margin-left: 0px;"><strong>BMI</strong>: VT 23 kg/m² (SD 3.5); BQT 23 kg/m² (SD 3) (P=0.89)</li>
<li style="margin-left: 0px;"><strong>Smoking</strong>: VT 15 (8.6%); BQT 9 (5.1%) (P=0.29)</li>
<li style="margin-left: 0px;"><strong>Alcohol drinking</strong>: VT 30 (17.1%); BQT 31 (17.7%) (P=1)</li>
<li style="margin-left: 0px;"><strong>Family history of gastric cancer</strong>: VT 17 (9.7%); BQT 20 (11.4%) (P=0.73)</li>
<li style="margin-left: 0px;"><strong>Penicillin allergy</strong>: VT 63 (36%); BQT 56 (32%) (P=0.50)</li>
<li style="margin-left: 0px;"><strong>Endoscopic findings</strong>: Gastritis VT 153 (87.4%) vs BQT 148 (84.6%); peptic ulcer VT 22 (12.6%) vs BQT 27 (15.4%)</li>
<li style="margin-left: 0px;"><strong>Concomitant diseases</strong>: VT 111 (63.4%); BQT 103 (58.9%) (P=0.44)</li>
<li style="margin-left: 0px;"><strong>Combined medicine use</strong>: VT 60 (34.3%); B</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>3. Previous Treatment History (continued)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>3.1 Number of Prior Eradication Failures</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Median number of previous treatment failures: VT group 2 (IQR 1-3); BQT group 2 (IQR 1-2) (P=0.052)</li>
<li style="margin-left: 0px;">Distribution of failures:</li>
<li style="margin-left: 20px;"><strong>1 prior failure</strong>: VT 65 (37.1%); BQT 77 (44%) (P=0.23)</li>
<li style="margin-left: 20px;"><strong>2 prior failures</strong>: VT 55 (31.4%); BQT 59 (33.7%) (P=0.73)</li>
<li style="margin-left: 20px;"><strong>≥3 prior failures</strong>: VT 55 (31.4%); BQT 39 (22.3%) (P=0.07)</li>
</ul>
</div></details>
<details><summary><strong>3.2 Types of Previous Regimens</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Tetracycline-based</strong>: VT 8 (4.6%); BQT 6 (3.4%) (P=0.79)</li>
<li style="margin-left: 0px;"><strong>Clarithromycin-based</strong>: VT 156 (89.1%); BQT 161 (92%) (P=0.47)</li>
<li style="margin-left: 0px;"><strong>Levofloxacin-based</strong>: VT 68 (38.9%); BQT 78 (44.6%) (P=0.33)</li>
<li style="margin-left: 0px;"><strong>Metronidazole-based</strong>: VT 95 (54.3%); BQT 79 (45.1%) (P=0.11)</li>
<li style="margin-left: 0px;"><strong>Furazolidone-based</strong>: VT 25 (14.3%); BQT 16 (9.1%) (P=0.18)</li>
<li style="margin-left: 0px;"><strong>Cephalosporin-based</strong>: VT 6 (3.4%); BQT 7 (4%) (P=1.00)</li>
<li style="margin-left: 0px;"><strong>Amoxicillin-based</strong> (times): median 1 (IQR 0-2) in both groups (P=0.48)</li>
<li style="margin-left: 20px;"><strong>0 prior amoxicillin courses</strong>: VT 57 (32.6%); BQT 50 (28.6%) (P=0.49)</li>
<li style="margin-left: 20px;"><strong>1 prior amoxicillin course</strong>: VT 46 (26.3%); BQT 63 (36%) (P=0.07)</li>
<li style="margin-left: 20px;"><strong>≥2 prior amoxicillin courses</strong>: VT 72 (41.1%); BQT 62 (35.4%) (P=0.32)</li>
</ul>
</div></details>
<details><summary><strong>3.3 Discontinuation Details</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT group discontinuations (n=2)</strong>:</li>
<li style="margin-left: 20px;">Patient #120: Male, 34 years, no penicillin allergy, 4 prior failures, stopped on day 10 due to travel (not TEAE-related), eradication successful</li>
<li style="margin-left: 20px;">Patient #049: Female, 27 years, no penicillin allergy, 1 prior failure, stopped on day 7 due to viral infection with fever after heavy alcohol consumption, eradication failed</li>
<li style="margin-left: 0px;"><strong>BQT group discontinuations (n=16)</strong>:</li>
<li style="margin-left: 20px;">15 patients discontinued due to TEAEs</li>
<li style="margin-left: 20px;">1 patient stopped on day 7 due to insomnia and anxiety related to personal stress</li>
<li style="margin-left: 20px;">Eradication outcomes: 10/16 (62.5%) achieved successful eradication</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Eradication Results (Primary Efficacy Outcomes)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.1 Intention-to-Treat (ITT) Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT group</strong>: 88.0% (154/175; 95% CI: 82.0%-92.2%)</li>
<li style="margin-left: 0px;"><strong>BQT group</strong>: 86.3% (151/175; 95% CI: 80.1%-90.8%)</li>
<li style="margin-left: 0px;"><strong>Difference</strong>: 1.7% (95% CI: –5.9% to 9.3%)</li>
<li style="margin-left: 0px;"><strong>P value for difference</strong>: 0.75</li>
<li style="margin-left: 0px;"><strong>Non-inferiority P value</strong>: 0.0005</li>
</ul>
</div></details>
<details><summary><strong>4.2 Modified Intention-to-Treat (mITT) Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT group</strong>: 90.6% (154/170; 95% CI: 84.9%-94.4%)</li>
<li style="margin-left: 0px;"><strong>BQT group</strong>: 89.3% (151/169; 95% CI: 83.5%-93.4%)</li>
<li style="margin-left: 0px;"><strong>Difference</strong>: 1.2% (95% CI: –5.7% to 8.2%)</li>
<li style="margin-left: 0px;"><strong>P value for difference</strong>: 0.84</li>
<li style="margin-left: 0px;"><strong>Non-inferiority P value</strong>: 0.0003</li>
</ul>
</div></details>
<details><summary><strong>4.3 Per-Protocol (PP) Analysis</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT group</strong>: 91.1% (153/168; 95% CI: 85.4%-94.7%)</li>
<li style="margin-left: 0px;"><strong>BQT group</strong>: 92.2% (141/153; 95% CI: 86.4%-95.7%)</li>
<li style="margin-left: 0px;"><strong>Difference</strong>: –1.1% (95% CI: –7.8% to 5.6%)</li>
<li style="margin-left: 0px;"><strong>P value for difference</strong>: 0.88</li>
<li style="margin-left: 0px;"><strong>Non-inferiority P value</strong>: 0.002</li>
</ul>
</div></details>
<details><summary><strong>4.4 Non-Inferiority Achievement</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy achieved predefined non-inferiority endpoint compared with BQT as rescue treatment across all analysis populations</li>
<li style="margin-left: 0px;">Non-inferiority criterion (P &lt; 0.01) met in ITT, mITT, and PP analyses</li>
<li style="margin-left: 0px;">No statistically significant difference in eradication efficacy between treatment groups in any analysis population</li>
</ul>
</div></details>
<details><summary><strong>4.5 Subgroup Analysis by Penicillin Allergy Status</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT group, no penicillin allergy</strong>: 91.8% (101/110; 95% CI: 86.4%-95.2%)</li>
<li style="margin-left: 0px;"><strong>VT group, with penicillin allergy</strong>: 88.3% (53/60; 95% CI: 79.8%-93.5%)</li>
<li style="margin-left: 0px;"><strong>BQT group, no penicillin allergy</strong>: 89.4% (101/113; 95% CI:</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Eradication Results (Primary Efficacy Outcomes) (continued)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>4.5 Subgroup Analysis by Penicillin Allergy Status (continued)</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>BQT group, with penicillin allergy</strong>: 89.3% (50/56; 95% CI: 80.6%-94.3%)</li>
<li style="margin-left: 0px;"><strong>Absolute difference VT vs BQT, no allergy</strong>: +2.4% (95% CI: –5.2% to 10.1%) (P=0.53)</li>
<li style="margin-left: 0px;"><strong>Absolute difference VT vs BQT, with allergy</strong>: –0.9% (95% CI: –12.4% to 10.5%) (P=0.87)</li>
<li style="margin-left: 0px;">No significant difference in eradication rates between patients with or without penicillin allergy in either group</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Safety and Tolerability (Secondary Outcomes)</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>5.1 Overall Treatment-Emergent Adverse Events</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Total TEAEs</strong>: VT group 19/175 (10.9%); BQT group 80/175 (45.7%) (P &lt; 0.001)</li>
<li style="margin-left: 0px;">VT dual therapy showed significantly lower overall incidence of TEAEs compared to BQT</li>
</ul>
</div></details>
<details><summary><strong>5.2 Adverse Events by Severity Grade</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Mild TEAEs</strong>: VT 13 patients; BQT 54 patients (P &lt; 0.001)</li>
<li style="margin-left: 0px;"><strong>Moderate TEAEs</strong>: VT 4 patients; BQT 10 patients (P = 0.17)</li>
<li style="margin-left: 0px;"><strong>Severe TEAEs</strong>: VT 2 patients; BQT 16 patients (P = 0.001)</li>
<li style="margin-left: 0px;"><strong>Moderate to severe combined</strong>: VT 6 patients; BQT 26 patients (P &lt; 0.001)</li>
<li style="margin-left: 0px;">Significant difference observed for mild and severe TEAEs; moderate TEAEs not statistically different</li>
</ul>
</div></details>
<details><summary><strong>5.3 Specific Adverse Events</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Nausea</strong>: VT 3; BQT 37</li>
<li style="margin-left: 0px;"><strong>Diarrhea</strong>: VT 1; BQT 12</li>
<li style="margin-left: 0px;"><strong>Abdominal pain</strong>: VT 2; BQT 9</li>
<li style="margin-left: 0px;"><strong>Bitter taste</strong>: VT 0; BQT 8</li>
<li style="margin-left: 0px;"><strong>Constipation</strong>: VT 5; BQT 7</li>
<li style="margin-left: 0px;"><strong>Dizziness</strong>: VT 2; BQT 6</li>
<li style="margin-left: 0px;"><strong>Fatigue</strong>: VT 1; BQT 6</li>
<li style="margin-left: 0px;"><strong>Vomiting</strong>: VT 0; BQT 6</li>
<li style="margin-left: 0px;"><strong>Dry mouth</strong>: VT 0; BQT 6</li>
<li style="margin-left: 0px;"><strong>Fever</strong>: VT 1; BQT 5</li>
<li style="margin-left: 0px;"><strong>Headache</strong>: VT 0; BQT 4</li>
<li style="margin-left: 0px;"><strong>Loss of appetite</strong>: VT 0; BQT 3</li>
<li style="margin-left: 0px;"><strong>Abdominal distension</strong>: VT 3; BQT 2</li>
<li style="margin-left: 0px;"><strong>Abdominal discomfort</strong>: VT 1; BQT 2</li>
<li style="margin-left: 0px;"><strong>Itchy skin</strong>: VT 1; BQT 2</li>
<li style="margin-left: 0px;"><strong>Rash</strong>: VT 0; BQT 2</li>
<li style="margin-left: 0px;"><strong>Palpitation</strong>: VT 0; BQT 2</li>
<li style="margin-left: 0px;"><strong>Transient mild liver dysfunction</strong>: VT 1; BQT 1</li>
<li style="margin-left: 0px;"><strong>Chest tightness</strong>: VT 0; BQT 1</li>
<li style="margin-left: 0px;"><strong>Hypogeusia</strong>: VT 0; BQT 1</li>
<li style="margin-left: 0px;"><strong>Chest pain</strong>: VT 0; BQT 1</li>
<li style="margin-left: 0px;"><strong>Transient hand tremors</strong>: VT 0; BQT 1</li>
<li style="margin-left: 0px;"><strong>Muscle pain</strong>: VT 0; BQT 1</li>
<li style="margin-left: 0px;"><strong>Dreaminess</strong>: VT 0; BQT 1</li>
<li style="margin-left: 0px;"><strong>Glossitis</strong>: VT 1; BQT 0</li>
</ul>
</div></details>
<details><summary><strong>5.4 Discontinuation Due to Adverse Events</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT group</strong>: 0/175 (0.0%)</li>
<li style="margin-left: 0px;"><strong>BQT group</strong>: 15/175 (8.6%) (P &lt; 0.001)</li>
<li style="margin-left: 0px;">No patients in VT group discontinued treatment due to TEAEs</li>
<li style="margin-left: 0px;">All 15 discontinuations in BQT group were related to adverse events</li>
</ul>
</div></details>
<details><summary><strong>5.5 Adherence</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Overall adherence</strong> (≥80% of prescribed doses): VT 168/175 (96.0%); BQT 153/175 (87.4%) (P = 0.006)</li>
<li style="margin-left: 0px;"><strong>Adherence by AE grade</strong>:</li>
<li style="margin-left: 20px;">Mild TEAEs: VT 13/13 (100%); BQT 54/54 (100%)</li>
<li style="margin-left: 20px;">Moderate TEAEs: VT 4/4 (100%); BQT 10/10 (100%)</li>
<li style="margin-left: 20px;">Severe TEAEs: VT 2/2 (100%); BQT 4/16 (25%) (P = 0.10)</li>
</ul>
</div></details>
<details><summary><strong>5.6 Serious Outcomes</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No hospitalizations occurred in either group</li>
<li style="margin-left: 0px;">No deaths occurred in either group</li>
<li style="margin-left: 0px;">All adverse events resolved without intervention after treatment cessation</li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Discussion and Clinical Implications</strong></summary><div style="padding-left: 20px;">
<details><summary><strong>6.1 Efficacy Summary</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy was shown to be non-inferior to BQT as rescue treatment for H. pylori infection in patients with prior eradication failure</li>
<li style="margin-left: 0px;">High eradication rates achieved across ITT, mITT, and PP analyses, comparable to standard BQT</li>
<li style="margin-left: 0px;">First prospective evaluation of vonoprazan combined with tetracycline as simplified, penicillin-free rescue regimen</li>
</ul>
</div></details>
<details><summary><strong>6.2 Mechanistic Rationale</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Success of H. pylori eradication depends heavily on intensity, consistency, and duration of acid suppression</li>
<li style="margin-left: 0px;">Dual therapies became consistently favorable only when combined with double-dose PPIs or standard-dose P-CABs</li>
<li style="margin-left: 0px;">Potent acid suppression broadens applicability of dual therapy, allowing single sensitive antibiotic to achieve reliable eradication when gastric pH maintained ≥6 with P-CABs</li>
<li style="margin-left: 0px;">Pharmacologic rationale explains more favorable outcomes with VT dual therapy compared to omeprazole-tetracycline dual therapy in earlier studies</li>
</ul>
</div></details>
<details><summary><strong>6.3 Antibiotic Resistance Considerations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Major obstacle to successful eradication, particularly in rescue treatment</li>
<li style="margin-left: 0px;">Asia-Pacific surveillance data (1990-2022) showed resistance rates: metronidazole 52%, levofloxacin 26%, clarithromycin 22%</li>
<li style="margin-left: 0px;">Resistance to tetracycline and amoxicillin remained low at approximately 4%</li>
<li style="margin-left: 0px;">Empiric regimens built on low-resistance antibiotics more likely to remain effective in real-world settings</li>
<li style="margin-left: 0px;">Tetracycline resistance profile remains stable even after prior treatment failures</li>
</ul>
</div></details>
<details><summary><strong>6.4 Comparison with Previous Studies</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior randomized trial (treatment-naïve, penicillin-allergic patients): VT dual therapy achieved 94.5% eradication rate (mITT), comparable to BQT with significantly fewer adverse events (14.0% vs 48.0%)</li>
<li style="margin-left: 0px;">Prior real-world study: VT dual regimen achieved 90.9% eradication rate (40/44) as rescue therapy</li>
<li style="margin-left: 0px;">Present RCT results consistent: 90.6% eradication rate (VT, mITT) vs 90.9% in real-world study</li>
<li style="margin-left: 0px;">VT dual therapy demonstrated similar eradication rate to BQT (90.6% vs 89.3%), supporting its potential as optimized yet effective alternative for rescue treatment</li>
</ul>
</div></details>
<details><summary><strong>6.5 Treatment Optimization Strategy</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Evolving trend in H. pylori treatment seeks to optimize regimens by focusing on effective acid suppression combined with antibiotics with low resistance rates</li>
<li style="margin-left: 0px;">Strategy involves optimizing key components to achieve high eradication rates while reducing treatment complexity</li>
<li style="margin-left: 0px;">VT dual therapy fits well within this approach, offering simpler yet effective option reflecting advances in understanding bacterial susceptibility and treatment optimization</li>
<li style="margin-left: 0px;">VT regimen achieves simplification by removing one antibiotic without increasing dose of remaining antibiotic (tetracycline at standard 500 mg t.i.d. = 1.5 g/day vs conventional 2 g in BQT)</li>
</ul>
</div></details>
<details><summary><strong>6.6 Safety and Adherence Advantages</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Incidence of TEAEs significantly lower in VT group than BQT group (10.9% vs 45.7%, P &lt; 0.001)</li>
<li style="margin-left: 0px;">Fewer moderate or severe adverse events reported with VT therapy</li>
<li style="margin-left: 0px;">No treatment discontinuations due to adverse effects in VT group vs 15/16 patients in BQT group</li>
<li style="margin-left: 0px;">Higher adherence with VT dual therapy (96.0% vs 87.4%, P = 0.006)</li>
<li style="margin-left: 0px;">Favorable tolerability attributed to simplified dual regimen avoiding adverse effects commonly associated with multi-drug therapies</li>
</ul>
</div></details>
<details><summary><strong>6.7 Microbiota Considerations</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Adverse events related to eradication therapy include not only short-term symptoms but also potential long-term effects on gut microbiota</li>
<li style="margin-left: 0px;">VT dual therapy maintains tetracycline at standard dose without increasing overall antibiotic burden while omitting both bismuth and additional antibiotic used in BQT</li>
<li style="margin-left: 0px;">Streamlined composition may lead to less disruption of intestinal microbiota, representing potential therapeutic advantage</li>
</ul>
</div></details>
<details><summary><strong>6.8 Clinical Positioning</strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy and high-dose amoxicillin dual therapy are complementary options (no cross-resistance between tetracycline and amoxicillin)</li>
<li style="margin-left: 0px;">VT may serve as effective alternative for patients who have failed amoxicillin-based regimens</li>
</ul>
<p>-</p>
</div></details>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
